This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoang, K. Articles by Valantine, H. Search for Related Content PubMed PubMed Citation Articles by Hoang, K. Articles by Valantine, H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB FRUCTOSE STREPTOZOTOCIN Medline Plus Health Information Heart Transplantation

(Circulation. 1998;97:2160-2168.)
© 1998 American Heart Association, Inc.

Basic Science Reports

Diabetes and Dyslipidemia

A New Model for Transplant Coronary Artery Disease

Khanh Hoang, MD; Y.-D. Ida Chen, PhD; Gerald Reaven, MD; Lunan Zhang, MD; Heather Ross, MD; Margaret Billingham, MD; ; Hannah Valantine, MD

From the Division of Cardiovascular Medicine (K.H., Y.-D.I.C., G.R., L.Z., H.V.) and the Department of Pathology (M.B.), Stanford University, Stanford, Calif, and the Division of Cardiovascular Medicine, University of Toronto, Toronto, Ontario, Canada (H.R.).

Correspondence to Hannah Valantine, MD, Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Dr, Stanford, CA 94305-5246.

Background—Clinical observations suggest that transplant coronary artery disease (TxCAD) is immunologically mediated but may be accelerated by metabolic derangements. We developed a rat model of heterotopic heart transplantation in the presence of diabetes and dyslipidemia to further study their role in TxCAD development.

Methods and Results—Major histocompatibility complex–mismatched strains of inbred rats underwent heterotopic heart transplantation (ACI-to-Lewis allografts). Diabetes (DM) was induced by streptozotocin injection (80 mg/kg) after transplantation; dyslipidemia was worsened by feeding of a 60% high-fructose diet (+F). Allograft transplants were divided into four groups: (1) +DM/+F; (2) +DM/-F; (3) -DM/+F; and (4) -DM/-F. Isograft transplants (Lewis to Lewis, +DM/±F) were controls. All animals received daily cyclosporine (5 mg/kg). Grafts surviving >30 days were evaluated for TxCAD on histological sections and graded 0 to 5 for intimal thickness. All streptozotocin-treated animals were diabetic within 2 weeks, with fourfold increases in plasma glucose concentrations versus nondiabetics. Severe TxCAD was observed in diabetic allografts only. The mean grade of TxCAD in diabetic allografts was 3.2±0.5 versus 1.1±0.4 in diabetic isografts (P<0.03) and zero TxCAD in nondiabetic allografts (P0.0001). Fructose feeding resulted in a 1.5-fold higher triglyceride and a 1.3-fold higher cholesterol level versus the regular diet (-F) but showed no independent contribution to the development of TxCAD.

Conclusions—These findings suggest that metabolic derangements associated with diabetes play an important role in TxCAD development in heterotopic ACI-to-Lewis rat heart transplantation. In this model of TxCAD in major histocompatibility complex–mismatched, diabetic, and dyslipidemic rats, immunologic and metabolic mechanisms that contribute to TxCAD can be further delineated and approaches to its prevention assessed.

Key Words: transplantation • atherosclerosis • lipoproteins • diabetes mellitus • animal model

This article has been cited by other articles:

				T. Kato, M. C. Y. Chan, S.-Z. Gao, J. S. Schroeder, M. Yokota, T. Murohara, M. Iwase, A. Noda, S. A. Hunt, and H. A. Valantine Glucose intolerance, as reflected by hemoglobin a1c level, is associated with the incidence and severity of transplant coronary artery disease J. Am. Coll. Cardiol., March 17, 2004; 43(6): 1034 - 1041. [Abstract] [Full Text] [PDF]

				G. Vassalli, A. Gallino, M. Weis, W. von Scheidt, L. Kappenberger, L.K. von Segesser, J.-J. Goy, and on behalf of the Working Group Microcirculation of Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy Eur. Heart J., July 1, 2003; 24(13): 1180 - 1188. [Abstract] [Full Text] [PDF]

				M. Weis and J. P. Cooke Cardiac Allograft Vasculopathy and Dysregulation of the NO Synthase Pathway Arterioscler. Thromb. Vasc. Biol., April 1, 2003; 23(4): 567 - 575. [Abstract] [Full Text] [PDF]

				B. Cantin, P. Wen, D. Zhu, M. Dai, S. N. Panchal, M. E. Billingham, J. K. Gwathmey, and H. A. Valantine Transplant Coronary Artery Disease: A Novel Model Independent of Cellular Alloimmune Response Circulation, November 20, 2001; 104(21): 2615 - 2619. [Abstract] [Full Text] [PDF]

				L. W. Miller, E. Dai, P. Nash, L. Liu, C. Icton, D. Klironomos, L. Fan, P. N. Nation, R. Zhong, G. McFadden, et al. Inhibition of Transplant Vasculopathy in a Rat Aortic Allograft Model After Infusion of Anti-Inflammatory Viral Serpin Circulation, April 4, 2000; 101(13): 1598 - 1605. [Abstract] [Full Text] [PDF]